US pharmaceutical giant Eli Lilly, signed an agreement to divest the Baqsimi drug a Amphastar Pharmaceuticals, a pharmaceutical company focused on the development, manufacturing and marketing of injectable, intranasal and inhalation products. The understanding goes beyond that 1 billion dollars.
The drug Baqsimi
Baqsimi is the first and only nasally administered glucagon for the treatment ofsevere hypoglycemia in people with diabetes. Eli Lilly launched it in 2019 as an option to quickly provide help in emergency situations for people with diabetes who are on insulin. The drug spread very quickly, it is currently available in 27 international markets and Baqsimi's global sales surpassed ia 139 million dollars in 2022.
The deal between Eli Lilly and Amphastar
According to the provisions of the agreement. Amphastar will disburse 500 million dollars in cash at closing and further 125 million dollars one year after closing. Not only. Lilly will continue to receive payments based on sales up to a maximum of 450 million dollars.
After the announcement, on Wall Street, the title Ely Lilly it gained 0,2% to $386,1 per share.
